PHARMA PROJECT: what changed
Position among the sector peers
Sector benchmark: create a free account or sign in to use this tool.
You see every sector peer as a dot per ratio, with the company in two financial years and every ratio over five years against the sector.
What moved between 2024 and 2025
Largest movements
- Tangible fixed assets -€69,626
down €69,626 (-8.1%), from €861,391 to €791,764
of which Leasing and similar rights: -€63,721
- Cash +€11,865
new in 2025: €11,865
mainly Other debts (+€69,694) and Depreciation (+€69,626)
- Debts after one year -€102,889
down €102,889 (-22.3%), from €461,661 to €358,771
- Other debts +€69,694
up €69,694 (+23.6%), from €295,494 to €365,188
- Short-term financial debts -€20,386
no longer reported in 2025 (was €20,386)
- Profit (loss) carried forward -€11,278
down €11,278 (-1.4%), from -€827,904 to -€839,182
- Gross operating margin -€14,299
down €14,299 (-14.6%), from €98,259 to €83,959
- Financial charges -€1,394
down €1,394 (-5.2%), from €27,005 to €25,611
Change in the result, 2024 to 2025
For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.
Derived cash bridge
The bridge is derived from the 2024 and 2025 balance sheets and the 2025 result. There is no filed cash-flow statement. You see where the money came from and where it went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €862,958 | €806,013 | -€56,946 | -6.6% |
| Fixed assets | 21/28 | €861,391 | €791,764 | -€69,626 | -8.1% |
| Tangible fixed assets | 22/27 | €861,391 | €791,764 | -€69,626 | -8.1% |
| Land and buildings | 22 | €198,353 | €193,493 | -€4,860 | -2.5% |
| Furniture and vehicles | 24 | €3,136 | €2,091 | -€1,045 | -33.3% |
| Leasing and similar rights | 25 | €659,902 | €596,181 | -€63,721 | -9.7% |
| Current assets | 29/58 | €1,568 | €14,248 | +€12,681 | +809% |
| Cash at bank and in hand | 54/58 | - | €11,865 | +€11,865 | |
| Deferred charges and accrued income | 490/1 | €1,568 | €2,383 | +€815 | +52.0% |
| Total equity and liabilities | 10/49 | €862,958 | €806,013 | -€56,946 | -6.6% |
| Equity | 10/15 | -€22,018 | -€33,296 | -€11,278 | -51.2% |
| Contributions | 10/11 | €62,000 | €62,000 | = | 0.0% |
| Capital | 10 | €62,000 | €62,000 | = | 0.0% |
| Issued capital | 100 | €62,000 | €62,000 | = | 0.0% |
| Revaluation surpluses | 12 | €743,886 | €743,886 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€827,904 | -€839,182 | -€11,278 | -1.4% |
| Amounts payable | 17/49 | €884,976 | €839,308 | -€45,668 | -5.2% |
| Amounts payable after more than one year | 17 | €461,661 | €358,771 | -€102,889 | -22.3% |
| Financial debts | 170/4 | €461,661 | €358,771 | -€102,889 | -22.3% |
| Amounts payable within one year | 42/48 | €421,979 | €479,447 | +€57,469 | +13.6% |
| Current portion of amounts payable after more than one year | 42 | €103,388 | €102,889 | -€499 | -0.5% |
| Financial debts | 43 | €20,386 | - | -€20,386 | |
| Credit institutions | 430/8 | €20,386 | - | -€20,386 | |
| Trade debts | 44 | €1,651 | €9,878 | +€8,228 | +498% |
| Suppliers | 440/4 | €1,651 | €9,878 | +€8,228 | +498% |
| Taxes, remuneration and social security | 45 | €1,060 | €1,492 | +€432 | +40.7% |
| Taxes | 450/3 | €1,060 | €1,492 | +€432 | +40.7% |
| Other amounts payable | 47/48 | €295,494 | €365,188 | +€69,694 | +23.6% |
| Accrued charges and deferred income | 492/3 | €1,337 | €1,090 | -€247 | -18.5% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €69,626 | €69,626 | = | 0.0% |
| Gross operating margin | 9900 | €98,259 | €83,959 | -€14,299 | -14.6% |
| Operating profit (loss) | 9901 | €28,632 | €14,333 | -€14,299 | -49.9% |
| Financial charges | 65/66B | €27,005 | €25,611 | -€1,394 | -5.2% |
| Recurring financial charges | 65 | €27,005 | €25,611 | -€1,394 | -5.2% |
| Profit (loss) for the period before taxes | 9903 | €1,627 | -€11,278 | -€12,905 | |
| Profit (loss) for the period | 9904 | €1,627 | -€11,278 | -€12,905 | |
| Profit (loss) for the period to be appropriated | 9905 | €1,627 | -€11,278 | -€12,905 |
Value
latest balance sheet 30-06-2025 · indication, not a valuation or adviceIndicative value of the equity
Indication, not a valuation or adviceMidpoint €0 · adjusted equity only
Capitalisation rate 12% result over 3 years, excluding non-recurring income and charges earnings weight 50% revaluation €0 other adjustment €0 EBITDA multiple
The filed figures and these assumptions give no positive value. The adjusted equity and the average result are both zero or negative.
Part of the calculation comes out below zero. A shareholding is never worth less than zero, so the floor is zero.
Adjusted equity
- Equity (10/15)
- -€33,296
- Formation expenses (20)
- €0
- Intangible fixed assets (21)
- €0
- Revaluation of assets
- €0
- Deferred tax on the revaluation
- €0
- Other adjustment
- €0
- Adjusted equity
- -€33,296
Capitalised earnings
- 2025
- -€11,278
- 2024
- €1,627
- 2023
- -€13,986
- 2022
- -€11,819
- 2021
- -€5,237
- Average result, excluding non-recurring income and charges
- -€7,879
- Divided by the capitalisation rate
- 14% / 12% / 10%
- Capitalised earnings
- not meaningful, as the average result is zero or negative
Your EBITDA multiple
- EBITDA 2025
- €83,959
- Net financial debt
- €449,795
- Your multiple
- -
- Value with your multiple
- -
Net financial debt is the sum of financial debts after one year, the part due within the year and short-term financial debts, less cash and current investments.
Limits of the indication
- Checked holds no market prices or comparable transactions.
- Anything after the latest accounts and items off the balance sheet (guarantees, leases, disputes) are left out.
- Checked does not know the real value of buildings, stock and receivables. Enter your own revaluation or adjustment for it.
- The owner's role in the business, synergies for a buyer and the tax consequences of a sale are left out.
For a valuation to base a decision on, go to a company auditor or a certified accountant.
Next steps
Calculation and sources
Source: filed annual accounts (NBB) and main activity (KBO). The movements compare the financial years ended 30 June 2024 and 30 June 2025. Green is a favourable move for that line, red an unfavourable one. The value is an indication, not a valuation or advice. Prepared on 13 November 2026 via checked.be.